Key Molecular Drivers of Chronic Lymphocytic Leukemia

Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):593-606. doi: 10.1016/j.clml.2016.08.008. Epub 2016 Aug 10.

Abstract

Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of CLL. The present review describes what is known about these key molecules in the context of their role in tumor pathogenicity, prognosis, and therapy.

Keywords: CLL; Molecular drivers; Pathogenicity; Prognosis; Therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor
  • Disease Susceptibility
  • Gene Expression Regulation, Leukemic
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / etiology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • Prognosis
  • Signal Transduction

Substances

  • Biomarkers
  • Biomarkers, Tumor